Publication | Closed Access

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation

Metabolic SyndromeThrombosisDiabetes ManagementCardiovascular DiseaseBlood PlateletMedicineDiabetesHematologyPlatelet ActivityType 2Greater ReductionDiabetes MellitusPlatelet AntagonistPharmacologyHealth Sciences